Phaseline

Companies › Clarity Pharmaceuticals

Clarity Pharmaceuticals: clinical trials, targets and expected readouts

2 active drug programs in 4 registered trials: 2 Phase 3, 2 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
64Cu-SAR-bisPSMA
64Cu-labeled anti-PSMA bisPSMA antibody for imaging
PSMA, FOLH1Phase 3Prostate Cancer; Prostatic Neoplasms, Castration-ResistantDec 2026
67Cu-SAR-bisPSMA
67Cu-labeled anti-PSMA bisPSMA antibody for therapeutic targeting
PSMAPhase 1Prostatic Neoplasms, Castration-Resistant–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT0605683064Cu-SAR-bisPSMAPhase 3Prostate CancerOncologySep 2026
NCT0486860464Cu-SAR-bisPSMAPhase 1Prostatic Neoplasms, Castration-ResistantOncologySep 2026
NCT0486860467Cu-SAR-bisPSMAPhase 1Prostatic Neoplasms, Castration-ResistantOncologySep 2026
NCT0697084764Cu-SAR-bisPSMAPhase 3Prostate CancerOncologyDec 2026

Targets

PSMA (2) FOLH1 (1)

Companies with the same targets

Novartis Fusion Pharmaceuticals C Ray Therapeutics Curium US Johnson & Johnson (Janssen) Telix Pharmaceuticals (Innovations) Nova Therapeutics Eli Lilly Lantheus Medical Imaging Sinotau Pharmaceutical Group

Companies built like this

Fusion Pharmaceuticals Curium US Norroy Bioscience Lantheus Medical Imaging ABX advanced biochemical compounds

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.